Webinars » Identification of Relevant Antigenic Targets for Successful Liver Cancer Immunotherapy

Identification of Relevant Antigenic Targets for Successful Liver Cancer Immunotherapy

HCC is a major cause of cancer-related death in the world and the current available treatments are effective only at an early stage. For advanced HCC the only approved therapy is Sorafenib (a multi kinase inhibitor) which has low response rate (about 3%). New immunotherapies for HCC, like anti- PD-1 treatment, can achieve a higher response rate, but still in only a minority of patients (20%). To boost this rate, it is critical to guide the immune response towards relevant antigens expressed by all tumor cells. Genome-wide sequencing of HCC showed presence of mutations that theoretically could give rise to neoantigen-specific T cell responses. However, the presence of these immune responses has not been investigated yet. Our approach is to focus on mutations that are expressed on all cancer cells, like mutations in driver oncogenes. The central goal is to identify neoantigens in HCC and evaluate the presence of an immunological response to HCC- specific neoantigens with particular attention to hot-spot mutations in driver oncogenes.

In this webinar, we will cover

Background on Hepatocellular Carcinoma and how the liver microenvironment affects the immune cells

Relevant examples of successful/promising immunotherapies in hepatocellular carcinoma patients (cytokines, mAbs, TILs, CARs)

Our hypothesis: successful immunotherapy depends on targeting the relevant antigens

Our screening model: focus on specific genes that are clinically relevant for the tumor progression and identify T cell receptors able to recognize neoantigens within those genes

In this webinar, you will learn

Webinar Details

Date: April 10^th, 2019
Time: 9:00-9:45 AM EST, 2:00 – 2:45 PM EST
Speaker:

Anna Pasetto, Ph.D.

ssistant Professor, Karolinska Institutet

Anna Pasetto, PhD, recently joined the Karolinska Institute in Stockholm to work as assistant professor and managing director of the pre-GMP facility in the department of Laboratory Medicine. She received her Master Degree in Molecular Biotechnology in 2007 from Alma Mater Studiorum Bologna University, Italy. She then moved to the Karolinska Institute where she received her PhD in Immunology in 2012. Dr. Pasetto joined the laboratory of Dr. Steven Rosenberg at the National Cancer Institute, NIH in 2013 and her research was focused on the isolation of TCR genes from mutation-reactive tumor infiltrating lymphocytes in metastatic solid cancers.

Related Services

Peptide Services

Speaker-related Webinars

Identify the optimal protein purification strategy for your recombinant protein production

Identify the optimal protein purification strategy for your recombinant protein production

Are you challenged with obtaining sufficient amount of high purity proteins for your applications? Almost unavoidably, every protein purification step results in some degree of protein loss.

Recombinant protein expression & purification

Recombinant protein expression & purification

Are you struggling with the amount and/or purity of your recombinant protein? Attend this online seminar for solutions to the challenges in recombinant protein expression & purification.

Accelerating Lead Identification Through Paramagnetic Bead Purification Technology

Accelerating Lead Identification Through Paramagnetic Bead Purification Technology

High throughput purification is a critical step in antibody engineering and lead identification. Paramagnetic bead technology allows a single step purification of targets by simply adding the beads directly

Efficient stable cell pool/cell line development for large-scale antibody and protein production

Efficient stable cell pool/cell line development for large-scale antibody and protein production

Interested in rapid and efficient stable cell pool/cell line development for large-scale production of your recombinant antibodies and proteins? If so, this webinar may be for you.

Chaperone co expression strategies for recombinant soluble protein production in <em>E. Coli</em>

Chaperone co expression strategies for recombinant soluble protein production in E. Coli

Recombinant protein expression in E. coli often results in the formation of insoluble aggregates called inclusion bodies.

Latest Webinars

Find More Peptide Categories »

Applications and Challenges of Neoantigen Peptides in Personalized Cancer Vaccines

Applications and Challenges of Neoantigen Peptides in Personalized Cancer Vaccines

Harnessing mRNA immunization strategy for challenging GPCR protein antibody discover

Harnessing mRNA immunization strategy for challenging GPCR protein antibody discover

Enhancing Precision Medicine: GenScript's Expansion into GMP grade API Production and Neoantigen Peptide Synthesis

Enhancing Precision Medicine: GenScript's Expansion into GMP grade API Production and Neoantigen Peptide Synthesis